• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TransMedics Group Inc. (Amendment)

    2/13/24 5:15:57 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TMDX alert in real time by email
    SC 13G/A 1 tv02099-transmedicsgroupinc.htm SCHEDULE 13G/A transmedicsgroupinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  TransMedics Group Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  89377M109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  89377M109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    58,097

    7.  SOLE DISPOSITIVE POWER

    1,772,621

    8.  SHARED DISPOSITIVE POWER

    92,494

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,865,115

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.71%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    TransMedics Group Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    200 Minuteman Road, Suite 302
    Andover, MA 01810

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    89377M109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $TMDX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TMDX

    DatePrice TargetRatingAnalyst
    12/17/2024$116.00 → $75.00Overweight → Neutral
    Analyst
    11/22/2024Buy → Hold
    Needham
    10/29/2024$200.00 → $125.00Outperform
    Oppenheimer
    10/29/2024$208.00 → $109.00Buy
    Needham
    9/24/2024$200.00Outperform
    Robert W. Baird
    8/21/2024$208.00Buy
    Needham
    6/6/2024$161.00Overweight
    Cantor Fitzgerald
    6/4/2024$151.00Overweight
    Stephens
    More analyst ratings

    $TMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TransMedics Group downgraded by Analyst with a new price target

      Analyst downgraded TransMedics Group from Overweight to Neutral and set a new price target of $75.00 from $116.00 previously

      12/17/24 8:22:54 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Group downgraded by Needham

      Needham downgraded TransMedics Group from Buy to Hold

      11/22/24 8:05:47 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Oppenheimer reiterated coverage on TransMedics Group with a new price target

      Oppenheimer reiterated coverage of TransMedics Group with a rating of Outperform and set a new price target of $125.00 from $200.00 previously

      10/29/24 7:47:16 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025

      ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for dome

      7/16/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      ANDOVER, Mass., May 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 21, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 9,940 shares of its common stock and an aggregate of 6,670 restricted stock units to 15 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) an

      5/27/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Present at Upcoming June Investor Conferences

      ANDOVER, Mass., May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to present at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on Monday, June 9, 2025, at 8:00 a.m. EST.

      5/20/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    SEC Filings

    See more
    • SEC Form SD filed by TransMedics Group Inc.

      SD - TransMedics Group, Inc. (0001756262) (Filer)

      5/30/25 4:15:33 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by TransMedics Group Inc.

      144 - TransMedics Group, Inc. (0001756262) (Subject)

      5/27/25 4:18:07 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 8-K filed by TransMedics Group Inc.

      8-K - TransMedics Group, Inc. (0001756262) (Filer)

      5/23/25 4:15:26 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Ranganath Anil P. sold $95,903 worth of shares (686 units at $139.80), decreasing direct ownership by 5% to 13,955 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      6/10/25 4:44:58 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Basile Edward M exercised 5,000 shares at a strike of $0.70 and sold $632,250 worth of shares (5,000 units at $126.45) (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      5/29/25 4:30:11 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Basile Edward M was granted 2,134 shares, increasing direct ownership by 292% to 2,866 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      5/23/25 6:48:25 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

      ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

      12/2/24 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

      9/26/24 6:04:00 PM ET
      $CCRN
      $CHK
      $ENSG
      $SITC
      Professional Services
      Consumer Discretionary
      Oil & Gas Production
      Energy
    • TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary

      ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be

      7/26/23 5:09:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Financials

    Live finance-specific insights

    See more
    • TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025

      ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for dome

      7/16/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

      ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domesti

      4/24/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/7/24 11:37:08 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/4/24 4:23:23 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by TransMedics Group Inc. (Amendment)

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      2/14/24 6:28:57 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care